INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,744,858 | -23.3% | 33,497 | -6.8% | 0.00% | -33.3% |
| Q2 2023 | $2,274,960 | +17.1% | 35,928 | +0.1% | 0.00% | 0.0% |
| Q1 2023 | $1,943,008 | +2.3% | 35,882 | -0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,898,928 | +12.9% | 35,883 | -0.7% | 0.00% | 0.0% |
| Q3 2022 | $1,682,000 | -18.4% | 36,126 | +0.0% | 0.00% | 0.0% |
| Q2 2022 | $2,062,000 | -17.1% | 36,123 | -11.1% | 0.00% | 0.0% |
| Q1 2022 | $2,486,000 | +12.8% | 40,624 | -3.5% | 0.00% | 0.0% |
| Q4 2021 | $2,203,000 | +37.5% | 42,081 | -2.1% | 0.00% | +50.0% |
| Q3 2021 | $1,602,000 | -1.3% | 42,991 | +8.1% | 0.00% | 0.0% |
| Q2 2021 | $1,623,000 | +19.0% | 39,770 | -1.1% | 0.00% | 0.0% |
| Q1 2021 | $1,364,000 | +39.6% | 40,203 | +30.8% | 0.00% | 0.0% |
| Q4 2020 | $977,000 | +18.1% | 30,733 | -4.6% | 0.00% | 0.0% |
| Q3 2020 | $827,000 | -5.7% | 32,210 | -5.8% | 0.00% | 0.0% |
| Q2 2020 | $877,000 | +245.3% | 34,180 | +107.3% | 0.00% | +100.0% |
| Q1 2020 | $254,000 | -47.0% | 16,490 | +18.0% | 0.00% | 0.0% |
| Q4 2019 | $479,000 | +374.3% | 13,975 | +3.5% | 0.00% | – |
| Q3 2019 | $101,000 | -47.1% | 13,500 | -8.2% | 0.00% | – |
| Q2 2019 | $191,000 | +6.7% | 14,700 | 0.0% | 0.00% | -100.0% |
| Q1 2019 | $179,000 | +7.2% | 14,700 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $167,000 | -47.6% | 14,700 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $319,000 | +22.7% | 14,700 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $260,000 | -14.5% | 14,700 | +2.1% | 0.00% | 0.0% |
| Q1 2018 | $304,000 | +45.5% | 14,400 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $209,000 | -11.1% | 14,400 | -3.0% | 0.00% | 0.0% |
| Q3 2017 | $235,000 | +34.3% | 14,850 | +5.3% | 0.00% | 0.0% |
| Q2 2017 | $175,000 | -23.6% | 14,100 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $229,000 | +7.5% | 14,100 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $213,000 | -0.9% | 14,100 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $215,000 | -65.4% | 14,100 | -11.9% | 0.00% | -66.7% |
| Q2 2016 | $622,000 | +58.7% | 16,000 | +13.5% | 0.00% | +50.0% |
| Q1 2016 | $392,000 | -68.3% | 14,100 | -38.7% | 0.00% | -66.7% |
| Q4 2015 | $1,237,000 | +136.1% | 23,000 | +75.6% | 0.01% | +100.0% |
| Q3 2015 | $524,000 | -37.5% | 13,100 | -50.0% | 0.00% | +50.0% |
| Q2 2015 | $838,000 | +185.0% | 26,200 | +113.0% | 0.00% | 0.0% |
| Q1 2015 | $294,000 | +34.9% | 12,300 | 0.0% | 0.00% | +100.0% |
| Q4 2014 | $218,000 | – | 12,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |